|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600117693 |
|
最近更新日期: Date of Last Refreshed on: |
2026-01-27 18:02:54 |
|
注册时间: Date of Registration: |
2026-01-27 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于多模态深度学习识别轻中度支气管哮喘临床表型及决策树模型构建:队列研究 |
|
Public title: |
Identification of Clinical Phenotypes in Mild-to-Moderate Bronchial Asthma Based on Multimodal Deep Learning and Construction of a Decision Tree Model: A Cohort Study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于多模态深度学习识别轻中度支气管哮喘临床表型及决策树模型构建:队列研究 |
|
Scientific title: |
Identification of Clinical Phenotypes in Mild-to-Moderate Bronchial Asthma Based on Multimodal Deep Learning and Construction of a Decision Tree Model: A Cohort Study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张雪 |
研究负责人: |
张雪 |
|
Applicant: |
Xue Zhang |
Study leader: |
Xue Zhang |
|
申请注册联系人电话: Applicant telephone: |
+86 158 0056 2053 |
研究负责人电话: Study leader's telephone: |
+86 158 0056 2053 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zx15800562053@163.com |
研究负责人电子邮件: Study leader's E-mail: |
zx15800562053@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市虹口区四川北路街道武进路85/86号 |
研究负责人通讯地址: |
上海市虹口区四川北路街道武进路85/86号 |
|
Applicant address: |
85/86 Wujin Road, Sichuan North Road Sub-district, Hongkou District, Shanghai, China |
Study leader's address: |
85/86 Wujin Road, Sichuan North Road Sub-district, Hongkou District, Shanghai, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海市第一人民医院 |
||
|
Applicant's institution: |
Shanghai General Hospital |
||
|
研究负责人所在单位: |
上海市第一人民医院 |
||
|
Affiliation of the Leader: |
Shanghai General Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
院伦快[2025]843 号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海市第一人民医院人体试验伦理审查委员会 |
||
|
Name of the ethic committee: |
Shanghai General Hospital Institutional Review Board |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-12-30 00:00:00 |
||
|
伦理委员会联系人: |
耿雯倩 |
||
|
Contact Name of the ethic committee: |
Wenqian Geng |
||
|
伦理委员会联系地址: |
上海市虹口区四川北路街道武进路85/86号 |
||
|
Contact Address of the ethic committee: |
85/86 Wujin Road, Sichuan North Road Sub-district, Hongkou District, Shanghai, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 3612 6254 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
上海市第一人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shanghai General Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市虹口区四川北路街道武进路85/86号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
85/86 Wujin Road, Sichuan North Road Sub-district, Hongkou District, Shanghai, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
上海市第一人民医院特色研究项目资助 |
||||||||||||||||||||||
|
Source(s) of funding: |
Clinical Research Innovation Plan of Shanghai General Hospital |
||||||||||||||||||||||
|
Target disease: |
Asthma |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
1.1 构建并验证一个基于多模态深度学习的轻中度哮喘临床表型识别模型。 1.2 基于表型识别,构建并验证用于指导临床诊疗决策的可解释决策树模型。 |
||||||||||||||||||||||
|
Objectives of Study: |
1.1 Develop and validate a multimodal deep learning-based clinical phenotype identification model for mild-to-moderate asthma. 1.2 Based on phenotype identification, develop and validate an interpretable decision tree model to guide clinical diagnosis and treatment decision-making. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 受试者必须自愿参加此项研究及遵守研究规定,了解并遵守、配合相应检查,遵守用药剂量、随访计划,并自愿签署书面知情同意书。 2. 受试者年龄≥18岁,并≤70岁,不限男女和种族。 3. 反复发作喘息、气急、胸闷或咳嗽,时间≥8周。 4. 支气管舒张剂使用前FEV1≥70%预计值且支气管舒张剂使用后FEV1/FVC>0.7。 5. 血常规除嗜酸性粒细胞以外无明显异常,胸部CT无明显异常。 6. 可逆试验阳性。 7. 育龄期女性在试验期间采取有效的避孕措施。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Participants must voluntarily participate in this study, comply with the study regulations, understand and adhere to the required examinations, follow the prescribed medication dosage and follow-up schedule, and voluntarily provide written informed consent. 2. Participants must be aged >=18 years and <= 70 years, regardless of gender or ethnicity. 3. Participants must have recurrent episodes of wheezing, shortness of breath, chest tightness, or coughing lasting ≥8 weeks. 4. Pre-bronchodilator FEV1 must be ≥70% of the predicted value, and post-bronchodilator FEV1/FVC must be >0.7. 5. Complete blood count must show no significant abnormalities other than eosinophils, and chest CT must show no significant abnormalities. 6. Bronchodilator reversibility test must be positive. 7. Women of childbearing potential must use effective contraception during the trial period. |
||||||||||||||||||||||
|
排除标准: |
1. 不能配合哮喘诊断的相关检查或其他原因不能合作者。 2. 8周内呼吸道感染症状。 3. ACEI、ARB、β受体阻滞剂使用中。 4. 伴COPD、间质性肺炎等明确的其他类型慢性呼吸系统疾病病史;合并其它系统(如心血管、代谢、免疫、神经、泌尿及血液等)严重疾患。 5. 酗酒或麻醉药物滥用史,或具有精神病史、对抗性格、不良动机、多疑或其他情感或智力问题等可能影响参与此研究的知情有效性的情况。 6. 吸烟患者或戒烟不满6个月;戒烟满6个周,但吸烟量超过10包年。 7. 回顾性队列:临床数据或影像学资料缺失严重,无法满足分析要求。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Inability to cooperate with asthma diagnostic tests or other reasons preventing effective cooperation. 2. Respiratory infection symptoms within the past 8 weeks. 3. Current use of ACEI, ARB, or beta-blockers. 4. History of other definite chronic respiratory diseases such as COPD or interstitial pneumonia; presence of severe systemic comorbidities (e.g., cardiovascular, metabolic, immune, neurological, urinary, or hematological diseases). 5. History of alcohol abuse or narcotic drug abuse, or psychiatric history, antagonistic personality, ill motives, paranoia, or other emotional or intellectual issues that may impair the validity of informed consent for study participation. 6. Current smokers or those who quit smoking less than 6 months ago; or those who quit smoking for 6 weeks but have a smoking history exceeding 10 pack-years. 7. Retrospective cohort: Severe missing clinical or imaging data, rendering the information inadequate for analysis. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-07-03 00:00:00至 To 2027-07-03 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-02-01 00:00:00 至 To 2027-07-03 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不涉及 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究负责人邮件询问 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Email the study leader |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |